Table 3.
Multivariable analysis of target genes in microarray datasets
| GSE8970-GPL96 | GSE12417-GPL96 | GSE12417-GPL570 | |||||||
|---|---|---|---|---|---|---|---|---|---|
| OS | PFS | OS | OS | ||||||
| HR (95% CI) | p | HR (95% CI) | p | HR (95% CI) | p | HR (95% CI) | p | ||
| ACOT11 | ACOT11 expression, high vs. low | 0.658(0.296,1.462) | 0.304 | 0.636(0.287,1.405) | 0.263 | 1.445(0.970,2.154) | 0.07 | 1.809(1.009,3.243) | 0.047 |
| Age, per 10-year increase | 1.201(0.704,2.048) | 0.501 | 1.212(0.716,2.053) | 0.474 | 1.295(1.126,1.490) | <0.001 | 1.400(1.088,1.800) | 0.009 | |
| Sex, male vs. female | 1.326(0.473,3.717) | 0.592 | 1.369(0.488,3.838) | 0.551 | NA | NA | NA | NA | |
| Prior myelodysplastic syndrome | 0.685(0.270,1.741) | 0.427 | 0.711(0.281,1.795) | 0.470 | NA | NA | NA | NA | |
| Organ dysfunction | 1.162(0.490,2.753) | 0.733 | 1.253(0.536,2.930) | 0.603 | NA | NA | NA | NA | |
| FAB subtype | NA | NA | NA | NA | 0.879(0.773,0.999) | 0.048 | 0.956(0.778,1.174) | 0.667 | |
| FAXDC2 | FAXDC2 expression, high vs. low | 0.922(0.420.2.023) | 0.839 | 1(0.462,2.166) | >0.99 | 0.869(0.590,1.280) | 0.477 | 0.791(0.444,1.406) | 0.424 |
| Age, per 10-year increase | 1.185(0.685,2.051) | 0.544 | 1.182(0.688,2.030) | 0.545 | 1.278(1.114,1.466) | <0.001 | 1.382(1.074,1.778) | 0.012 | |
| Sex, male vs. female | 1.553(0.589,4.094) | 0.373 | 1.662(0.636,4.339) | 0.300 | NA | NA | NA | NA | |
| Prior myelodysplastic syndrome | 0.681(0.265,1.753) | 0.426 | 0.698(0.273,1.783) | 0.452 | NA | NA | NA | NA | |
| Organ dysfunction | 1.094(0.471,2.539) | 0.835 | 1.164(0.509,2.662) | 0.719 | NA | NA | NA | NA | |
| FAB subtype | NA | NA | NA | NA | 0.862(0.762,0.976) | 0.019 | 0.965(0.782,1.192) | 0.744 | |
| FECH | FECH expression, high vs. low | 0.363(0.149,0.883) | 0.025 | 0.390(0.163,0.934) | 0.034 | 0.566(0.382,0.838) | 0.005 | 0.424(0.235,0.764) | 0.004 |
| Age, per 10-year increase | 1.050(0.625,1.762) | 0.854 | 1.066(0.639,1.779) | 0.806 | 1.277(1.109,1.470) | 0.001 | 1.410(1.095,1.817) | 0.008 | |
| Sex, male vs. female | 1.932(0.734,5.089) | 0.183 | 1.988(0.763,5.181) | 0.160 | NA | NA | NA | NA | |
| Prior myelodysplastic syndrome | 0.452(0.169,1.204) | 0.112 | 0.486(0.184,1.284) | 0.146 | NA | NA | NA | NA | |
| Organ dysfunction | 1.684(0.653,4.343) | 0.281 | 1.781(0.697,4.554) | 0.228 | NA | NA | NA | NA | |
| FAB subtype | NA | NA | NA | NA | 0.855(0.757,0.967) | 0.013 | 0.978(0.790,1.210) | 0.837 | |
| HBD | HBD expression, high vs. low | 0.396(0.166,0.942) | 0.036 | 0.430(0.183,1.011) | 0.053 | 0.528(0.356,0.783) | 0.001 | 0.479(0.266,0.862) | 0.014 |
| Age, per 10-year increase | 1.015(0.594,1.732) | 0.957 | 1.035(0.610,1.756) | 0.898 | 1.294(1.126,1.487) | <0.001 | 1.363(1.070,1.738) | 0.012 | |
| Sex, male vs. female | 2.086(0.738,5.898) | 0.166 | 2.125(0.765,5.905) | 0.148 | NA | NA | NA | NA | |
| Prior myelodysplastic syndrome | 0.595(0.221,1.605) | 0.305 | 0.627(0.236,1.666) | 0.349 | NA | NA | NA | NA | |
| Organ dysfunction | 1.479(0.595,3.681) | 0.400 | 1.576(0.637,3.895) | 0.325 | NA | NA | NA | NA | |
| FAB subtype | NA | NA | NA | NA | 0.861(0.763,0.973) | 0.016 | 0.995(0.805,1.229) | 0.96 | |
| KLF1 | KLF1 expression, high vs. low | 0.457(0.208,1.000) | 0.050 | 0.429(0.198,0.927) | 0.031 | 0.560(0.379,0.829) | 0.004 | 0.581(0.325,1.037) | 0.066 |
| Age, per 10-year increase | 1.061(0.609,1.849) | 0.834 | 1.062(0.613,1.840) | 0.830 | 1.281(1.111,1.476) | 0.001 | 1.382(1.087,1.756) | 0.008 | |
| Sex, male vs. female | 1.928(0.693,5.362) | 0.209 | 2.064(0.742,5.738) | 0.165 | NA | NA | NA | NA | |
| Prior myelodysplastic syndrome | 0.562(0.204,1.547) | 0.265 | 0.574(0.208,1.584) | 0.284 | NA | NA | NA | NA | |
| Organ dysfunction | 1.184(0.492,2.845) | 0.706 | 1.259(0.530,2.994) | 0.602 | NA | NA | NA | NA | |
| FAB subtype | NA | NA | NA | NA | 0.853(0.755,0.963) | 0.011 | 0.976(0.791,1.204) | 0.821 | |
| LEF1 | LEF1 expression, high vs. low | 0.273(0.117,0.638) | 0.003 | 0.287(0.126,0.655) | 0.003 | 0.605(0.407,0.901) | 0.013 | 0.382(0.209,0.700) | 0.002 |
| Age, per 10-year increase | 1.328(0.789,2.236) | 0.285 | 1.342(0.802,2.245) | 0.263 | 1.259(1.094,1.449) | 0.001 | 1.423(1.099,1.843) | 0.007 | |
| Sex, male vs. female | 2.475(0.793,7.723) | 0.119 | 2.511(0.821,7.673) | 0.106 | NA | NA | NA | NA | |
| Prior myelodysplastic syndrome | 0.554(0.208,1.479) | 0.239 | 0.595(0.225,1.573) | 0.295 | NA | NA | NA | NA | |
| Organ dysfunction | 1.021(0.406,2.586) | 0.966 | 1.109(0.450,2.733) | 0.823 | NA | NA | NA | NA | |
| FAB subtype | NA | NA | NA | NA | 0.870(0.766,0.988) | 0.031 | 1.031(0.829,1.282) | 0.785 | |
| SLC25A37 | SLC25A37 expression, high vs. low | 0.312(0.117,0.827) | 0.019 | 0.294(0.111,0.782) | 0.014 | 0.540(0.360,0.808) | 0.003 | 0.616(0.345,1.101) | 0.102 |
| Age, per 10-year increase | 0.963(0.554,1.674) | 0.894 | 0.961(0.557,1.661) | 0.888 | 1.292(1.122,1.488) | <0.001 | 1.389(1.084,1.778) | 0.009 | |
| Sex, male vs. female | 1.431(0.548,3.737) | 0.465 | 1.474(0.568,3.828) | 0.425 | NA | NA | NA | NA | |
| Prior myelodysplastic syndrome | 0.336(0.106,1.065) | 0.064 | 0.332(0.105,1.058) | 0.062 | NA | NA | NA | NA | |
| Organ dysfunction | 1.377(0.573,3.310) | 0.475 | 1.494(0.629,3.552) | 0.363 | NA | NA | NA | NA | |
| FAB subtype | NA | NA | NA | NA | 0.897(0.792,1.015) | 0.086 | 0.983(0.796,1.214) | 0.872 | |
| UBE2E1 | UBE2E1 expression, high vs. low | 3.5(1.08,11.33) | 0.04 | 3.9(1.27,11.98) | 0.02 | 1.28(0.77,2.12) | 0.04 | 2.02(1.8,3.79) | 0.03 |
| Age, per 10-year increase | 1.04(0.96,1.13) | 0.32 | 1.04(0.96,1.12) | 0.35 | 1.02(1.00,1.04) | 0.03 | 1.36(1.07,1.73) | 0.01 | |
| Sex, male vs. female | 1.22(0.39,3.81) | 0.74 | 1.51(0.52,4.42) | 0.45 | NA | NA | NA | NA | |
| Prior myelodysplastic syndrome | 0.83(0.25,2.72) | 0.75 | 0.88(0.29,2.71) | 0.83 | NA | NA | NA | NA | |
| Organ dysfunction | 0.96(0.33,2.81) | 0.94 | 0.99(0.37,2.6) | 0.98 | NA | NA | NA | NA | |
| FAB subtype | NA | NA | NA | NA | 0.87(0.74,1.0) | 0.1 | 1.06(0.85,1.32) | 0.61 | |
NA not available